Metformin From Diabetes Management to Broader Applications in Weight Reduction and Metabolic Health
DOI:
https://doi.org/10.12775/QS.2024.35.56494Keywords
Metformin, Weight reduction, Biguanides, Mechanisms of action, Increased insulin sensitivity, Polycystic ovary syndrome (PCOS)Abstract
Introduction
Metformin is a widely used oral hypoglycemic agent for type 2 diabetes, with origins in medieval European medicine through the use of Galega officinalis. Subsequent centuries of research led to the development of synthetic biguanides, with metformin's approval as an antidiabetic agent in 1957. Since then, its therapeutic applications have broadened to address other metabolic and endocrine disorders, such as obesity, polycystic ovary syndrome (PCOS), and antipsychotic-induced weight gain.
Purpose of the Study
This study aims to review metformin's pharmacological properties, mechanisms of action, and its expanded clinical applications. Specifically, it focuses on metformin’s role in promoting weight loss and improving metabolic health across diverse patient populations, including those without diabetes. The study also addresses evidence gaps and proposes areas for further research on dose optimization and safety in non-diabetic populations.
Materials and Methods
A systematic literature review was conducted using databases such as PubMed and Google Scholar, focusing on studies examining metformin's effects on glycemic control, weight reduction, and metabolic stability.
Conclusions
Metformin's history underscores its evolution from traditional remedies to a versatile pharmacological agent for treating diabetes and other metabolic conditions. Ongoing research is essential to fully establish its optimal therapeutic parameters and long-term safety for diverse patient groups.
References
Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care. 1989 Sep;12(8):553-64. doi: 10.2337/diacare.12.8.553. PMID: 2673695.
Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 1991 Feb;229(2):181-7. doi: 10.1111/j.1365-2796.1991.tb00328.x. PMID: 1900072.
Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002 Jul 2;137(1):25-33. doi: 10.7326/0003-4819-137-1-200207020-00009. PMID: 12093242.
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002 Jul;51(7):2074-81. doi: 10.2337/diabetes.51.7.2074. PMID: 12086935.
Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG 4th, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004 Oct 15;279(42):43940-51. doi: 10.1074/jbc.M404421200. Epub 2004 Jul 19. Retraction in: J Biol Chem. 2019 Sep 6;294(36):13525. doi: 10.1074/jbc.W119.010595. PMID: 15265871.
Ryder JW, Yang J, Galuska D, Rincón J, Björnholm M, Krook A, Lund S, Pedersen O, Wallberg-Henriksson H, Zierath JR, Holman GD. Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients. Diabetes. 2000 Apr;49(4):647-54. doi: 10.2337/diabetes.49.4.647. PMID: 10871204.
Matthaei S, Reibold JP, Hamann A, Benecke H, Häring HU, Greten H, Klein HH. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology. 1993 Jul;133(1):304-11. doi: 10.1210/endo.133.1.8391425. PMID: 8391425.
Gunton JE, Delhanty PJ, Takahashi S, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003 Mar;88(3):1323-32. doi: 10.1210/jc.2002-021394. Erratum in: J Clin Endocrinol Metab. 2004 Jan;89(1):434. PMID: 12629126.
Hamann A, Benecke H, Greten H, Matthaei S. Metformin increases glucose transporter protein and gene expression in human fibroblasts. Biochem Biophys Res Commun. 1993 Oct 15;196(1):382-7. doi: 10.1006/bbrc.1993.2260. PMID: 8216316.
Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol. 1991 Feb;43(2):120-1. doi: 10.1111/j.2042-7158.1991.tb06645.x. PMID: 1672896.
Arner P. Free fatty acids--do they play a central role in type 2 diabetes? Diabetes Obes Metab. 2001 Aug;3 Suppl 1:S11-9. PMID: 11685824.
Abbasi F, Carantoni M, Chen YD, Reaven GM. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care. 1998 Aug;21(8):1301-5. doi: 10.2337/diacare.21.8.1301. PMID: 9702437.
Dominguez LJ, Davidoff AJ, Srinivas PR, Standley PR, Walsh MF, Sowers JR. Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology. 1996 Jan;137(1):113-21. doi: 10.1210/endo.137.1.8536601. PMID: 8536601.
Hui F, Zhang Y, Ren T, Li X, Zhao M, Zhao Q. Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2019 Apr;75(4):437-450. doi: 10.1007/s00228-018-2593-3. Epub 2018 Dec 3. PMID: 30511328.
McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014 Feb;168(2):178-84. doi: 10.1001/jamapediatrics.2013.4200. PMID: 24343296.
Veerman SRT, Cohen D. Preventie en behandeling van gewichts-toename bij antipsychotica [Prevention and treatment of antipsychotic induced weight gain]. Tijdschr Psychiatr. 2023;65(4):259-265. Dutch. PMID: 37323046.
Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011 Mar;25(3):299-305. doi: 10.1177/0269881109353461. Epub 2010 Jan 15. PMID: 20080925.
Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011 Mar;71(3):377-82. doi: 10.1111/j.1365-2125.2010.03783.x. PMID: 21284696; PMCID: PMC3045546.
Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update. 2009 Jan-Feb;15(1):57-68. doi: 10.1093/humupd/dmn043. Epub 2008 Oct 15. PMID: 18927072.
Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015 Sep-Oct;21(5):560-74. doi: 10.1093/humupd/dmv025. Epub 2015 Jun 9. Erratum in: Hum Reprod Update. 2016 Apr;22(3):408-9. doi: 10.1093/humupd/dmv063. PMID: 26060208.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Daniel Zapasek, Julia Słowik, Mateusz Bajak, Michał Szczepański, Maciej Mamczur, Marcin Kuliga, Julia Inglot, Jadwiga Inglot, Dominik Maciej Feret, Damian Sowa
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 37
Number of citations: 0